

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sub	stitute for form 1449A/B/	PTO		Complete If Known		
000		•	,	Application Number	10/532359-Conf. #1567	
IN	<b>IFORMATIC</b>	N DIS	CLOSURE	Filing Date	October 21, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Leong Ng	
				Art Unit	3762	
	(Use as many she ets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	ISA-03501	

U.S. PATENT DOCUMENTS							
Examiner	Ī	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	Cite No.1	Number-Kind Code <sup>2</sup> ( if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
/JS/	A1	US-5,290,678	03-01-1994	Jackowski			
1	A2	US-5,560,368	10-01-1996	Berger			
	A3	US-5,604,105	02-18-1997	Jackowski			
	A4	US-5,682,901	11-04-1997	Kamen	•		
	A5	US-5,710,008	01-20-1998	Jackowski			
	A6	US-6,348,585	02-19-2002	Culp et al.			
	A7	US-6,534,322	03-18-2003	Sabbadini			

П			FOREIG	GN PATENT D	OCUMENTS		
5		<u></u>	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Exar Initia		Cite No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>8</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T°
	t	B1	EP 0 291 194	02-16-94			
		B2	EP 1 102 196	05-23-01			
$\vdash$	T	В3	EP 1 241 479	09-18-02			
		B4	WO 00/31265	06-02-00			
┢	1	B5	WO 00/35951	06-22-00			
	1	В6	WO 02/32932	04-25-02			
$\vdash$	Т	1					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique (citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Exam Initial:	ņer	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		C1	Ames et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14", Nature, Vol. 401: pp. 282-286 (1999)				
		C2	Apple et al., "Preliminary Evaluation of the Vitros ECi Cardiac Troponin I Assay," Clin Chem., 46(4):572-4 (2000)				
		C3	Bottrill et al., "Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries," <i>British Journal of Pharmacology</i> , Vol. 130, No. 8:1865-1870 (2000)				
		C4	Brenner et al., "Diverse Biological Actions of Atrial Natriuretic Peptide," <i>Physiological Reviews</i> , Vol. 70, No. 3:665-699 (1990)				
		C5	Collinson et al., "Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice," <i>Heart</i> , 89(3):280-6 (2003)				
7	V	C6	Coulouarn et al., "Cioning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord" PNAS, Vol. 95:15803-15808 (1998)				

Date 05/16/2007				
	05/16/2007	Date	 	Examiner
Signature /Joseph Stoklosa/   Considered   GO/10/2007	 00/10/2007	Considered	/Joseph Stoklosa/	

Sub	stitute for form 1449A/E	урто		Complete If Known		
				Application Number	10/532359-Conf. #1567	
11	IFORMATIO	ON DIS	SCLOSURE	Filing Date	October 21, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Leong Ng	
Ū				Art Unit	3762	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	ISA-03501	

1	C7	Douglas et al., "Human Urotensin-II is a Potent Vasoactive Peptide: Pharmacological Characterization in the Rat, Mouse, Dog and Primate," Journal of Cardiovascular Pharmacology, Vol. 36, Suppl. 1: S163-S166 (2000)	
	C8	Douglas et al., "Congestive heart failure and expression of myocardial urotensin II," The Lancet, Vol. 359:1990-1997 (2002)	
	C9	Falahati et al., "Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction," <i>Am Heart J.</i> , 137(2):332-7 (1999)	
	C10	Hall, Christian, "The value of natriuretic peptides for the management of heart failure: current state of play," European Journal of Heart Failure, Vol. 3:395-397 (2001)	
	C11	Hillier et al., "Effects of Urotensin II in Human Arteries and Veins of Varying Caliber,"  Circulation; Vol. 103:1378-1381 (2001)	
	C12	Houghton et al., "Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography?," Int. Journal of Cardiology, 62:31-36 (1997)	
	C13	Hughes et al., "An immunoluminomeric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction," Clinical Science; Vol. 96:373-380 (1999)	
	C14	James et al., "N-terminal pro-brain natriuretic peptide and other risk marker the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a G Utilitization of Strategies to Open occluded arteries (GUSTO-IV) substudy," Circulation, 108(3):275-81 (2003)	
	C15	James et al., "Troponin and C-Reactive Protein Have Different Relations to Subsequent Mortality and Myocardial Infarction After Acute Coronary Syndrome," <i>J Am Coll Cardiol.</i> , 41(6):916-24 (2003)	
	C16	Karl et al., "Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit," Scand. J. Clin. Lab Invest., Vol. 59, Suppl. 230: 177-181 (1999)	
	C17	Koller et al., "Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide (CNP)," Science, Vol. 252:120-123 (1991)	
	C18	Lapp et al., "Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy," International Journal of Cardiology 94, 94:93-97 (2004)	
$\neg \neg$	C19	Le Moigne et al., "Determination of myoglobin: comparitive evaluation of the new automated VIDAS" assay with two other immunoassays," Clin Biochem., 35:255-62 (2002)	
	C20	Mair et al., "A Decision Tree for the Early Diagnosis of Acute Myocardial Infarction in Nontraumatic Chest Pain Patients at Hospital Admission," <i>Chest</i> , Vol. 106, No. 6:1502-1509 (1995)	
	C21	Mair et al, "Rapid accurate diagnosis of acute myocardial infarction in patients with non-traumatic chest pain within 1 h of admission," Coron Artery Dis 1995, 6(7): 539-45 (1995)	
	C22	Nielsen et al., "Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests," BMJ, 320:220-224 (2000)	
	C23	Ng et al., "Non-competitive immunochemiluminometric assay for cardiotrophin-I detects elevated plasma levels in human heart failure," Clinical Science, 102: 411-416 (2002)	
	C24	Ng et al., "Plasma urotensin in human systoric heart failure," Circulation 2002, 106:2877-2880 (2002)	
	C25	Omland, et al., "N-terminal pro-B-type natriuretic peptide and long arm mortality in acute coronary syndromes," Circulation, 106:2913-8 (2002)	_
	C26	Pearson et al., "Urotensin II: A somatostin-like peptide in the caudal neurosecretory system of fishes," PNAS, 77(8):5021-5024 (1980)	
	C27	Penttila et al, "Myoglobin, creatine kinase MB isoforms and creatine kinase MB mass in early diagnosis of myocardial infarction in patients with acute chest pain," Clin Biochem., 35:647-53 (2002)	
V	C28	Ribeiro et al., "Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease," The Lancet, 360:461-462 (2002)	_

Examiner Signature	/Joseph Stoklosa/	Date Considered	05/16/2007

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE onk Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/E	VPTO		Complete if Known		
000	34,010 101 101111 1440141			Application Number	10/532359-Conf. #1567	
IN	IFORMATIO	ON DISC	CLOSURE	Filing Date	October 21, 2003	
S	TATEMENT	BY AP	PLICANT	First Named Inventor	Leong Ng	
				Art Unit	3762	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	ISA-03501	

	C29	Richards, et al., "B type natriuretic peptides and ejection fraction for prognosis after mycardial infarction," Circulation, 107:2786-92 (2003)
	C30	Russell et al, "Cardiostimulant effects of urotensin-II in human heart in vitro," British Journal of Pharmacology, 132:5-9 (2001)
	C31	Russell et al., "Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure," Am. J. Physiol. Heart Circ. Physiol. 285:H1576-H1581 (2003)
	C32	Stingo et al., "Cardiovascular and renal actions of C-type natriuretic peptide," The American Physiological Society, H308-H312 (1992)
	C33	Stingo et al., "Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma" The American Physiological Society, H1318-H1321 (1992)
	C34	Stirrat et al. "Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries," Am. J. Heart Circ. Physiol., Vol. 280:H925-H928 (2001)
	C35	Suga et al., "Endothelial Production of C-Type Natriuretic Peptide and Its Marked Augmentation by Trasforming Growth Factor-β," <i>J. Clin, Invest.</i> , 90:1145-1149 (1992)
	C36	Tzanidis et al., "Direct Actions of Urotensin II on the Heart Implications for Cardiac Fibrosis and Hypertrophy," Circulation Research, 93(3):246-253 (2003)
	C37	Tzanidis et al., "Urotensin-II stimulates collagen synthesis by cardiac fibroblasts in vitr: implications for myocardial remodelling," ABSTRACT (2000)
	C38	Watanabe et al., "Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation," Journal of Hypertension; 19(12):2191-2196 (2001)
	C39	Zou et al., "Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats," Federation of European Biochemical Societies Letters, 508:57-60 (2001)
<b>├-₩</b>	C40	International Search Report dated January 29, 2004

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Joseph Stoklosa/	Date Considered	05/16/2007
Signature	70000pii Otokiosa/	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.